[HTML][HTML] Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

G Marucci, M Buccioni, D Dal Ben, C Lambertucci… - …, 2021 - Elsevier
Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …

Therapeutic approach to Alzheimer's disease: Current treatments and new perspectives

T Pardo-Moreno, A González-Acedo… - Pharmaceutics, 2022 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Acetylcholinesterase inhibitors: pharmacology and toxicology

MB Colovic, DZ Krstic… - Current …, 2013 - ingentaconnect.com
Acetylcholinesterase is involved in the termination of impulse transmission by rapid
hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the …

[HTML][HTML] Acetylcholinesterase inhibitors: pharmacology and toxicology

MB Čolović, DZ Krstić, TD Lazarević-Pašti… - Current …, 2013 - ncbi.nlm.nih.gov
Acetylcholinesterase is involved in the termination of impulse transmission by rapid
hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the …

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease

A Haake, K Nguyen, L Friedman… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine

R Khoury, J Rajamanickam… - … advances in drug …, 2018 - journals.sagepub.com
Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders
worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug …

Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review

S Ruangritchankul, P Chantharit… - … and Clinical Risk …, 2021 - Taylor & Francis
The rising of global geriatric population has contributed to increased prevalence of
dementia. Dementia is a neurodegenerative disease, which is characterized by progressive …

Natural polyphenols in the treatment of Alzheimer's disease

SB Syarifah-Noratiqah, I Naina-Mohamed… - Current drug …, 2018 - ingentaconnect.com
Neurodegenerative disease is an incurable disease which involves the degeneration or
death of the nerve cells. Alzheimer's Disease (AD) is a neurodegenerative disease …

[PDF][PDF] An update on drug treatment options of Alzheimer's disease

M Allgaier, C Allgaier - Front Biosci (Landmark Ed), 2014 - academia.edu
Introduction 3. Mechanisms underlying dementia of the Alzheimer type 4. Drugs approved
for the treatment of Alzheimer's disease 4.1. Acetylcholine esterase inhibitors 4.1. 1 …

The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review

S Arjmandi-Rad, JD Vestergaard Nieland… - Neurological …, 2024 - Springer
Objective Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the
most common type of dementia. The early diagnosis of AD is an important factor for the …